![](https://investorshub.advfn.com/uicon/416109.png?cb=1473126189)
Tuesday, July 23, 2019 6:11:46 PM
its hard not to like the fundamentals for MRKR.
The giant sell off is crazy looking but not uncommon for wall street short attack games to butcher the little biotech stocks like this.
I had studied the chart just enough to see that buying thr 5 dollar bottoms looked like a good entry. I feel like dismissing the lowest Plunged bottoms at 4 whatever and 2 whatever. I hope we dont see price fall below the critical 5 dollar step. at least not below 4.80 lets say. I agree with what Phantom said, that given the positive science,watching the price action is only about target hunting for best bargains to buy, and thats what I'm trying to do these days.
--------------------------------------------------------------
--------------------
In this giant downwave,that seems to be slowing down a little now, wouldnt you think that a plunge from 8.80 to first hit 6.50 and then settle at 6.15 might be an extreme pullback target to buy? In a normal price action wave pattern this 6.50-6.00 target area would be the standard Fibonacci target zone for a major pullback, one that would normally take place over a few months time at least.
But now, we have seen the resistance capping at 6.70 and then at 6 dollars now looking to fight the battle between 5.50 and 5.80 area to see if it will drop and bleed down another 50 cents to some lower targets before the final bottom gets developed. Unless it settles down here at 5.40.
---------------------------------------------------------------
I dont understand well the science fundamentals of complex biotech questions, and really appreciate the DD of others who understand it. I'm just a chart TA guy and I watch closely all the math and the patterns .
------------------------------------------------------------
It looks to me like buying at 6 dollars and 5.75 was ok. and any prices lower are ok. and the zone from 6 to 5 dollars just has to be seen as a buying zone if one is deciding from math patterns and chart price points.The sellers have shown strength to take it from 6 to 5.43 today. Can they do it again tomorrow and the rest of the week to the lower targets? The other day, for a moment the 5.76 looked like a great bargain to buy. At some future point, in a future rally, that 5.75 step will become a Shoulder zone, where support can develop . something to watch when the time comes. It didnt hold today. and now it functions as a Resistance step for tomorrow to watch out for. Lower targets are still in play . 5.50 looks like it wants to try and hold.
I remain cautious about it. I bought some here as well as 5.80 the other day, but waiting for the lower targets to make my final buys.
(Anyway,I'm not offering this as any advice for anyone,just my opinion and what I see on the chart)
-----------------------------------------------------------------
MRKR 5 minute chart
Good trading and investing to all.
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM